Physician profile
Thomas-Duythuc Ngoc To
NPI 1215129044
$338,564.78
in general payments reported to CMS, 2019-2025
32 companies · $127K in 2025
The $127K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,079 · 2021: $9,134 · 2022: $74K · 2023: $61K · 2024: $48K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $155K · Consulting Fee: $37K · Travel and Lodging: $27K · Food and Beverage: $16K · Education: $51.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,666.00 |
| Consulting Fee | $37,284.58 |
| Travel and Lodging | $26,878.31 |
| Food and Beverage | $16,471.83 |
| Education | $51.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $220,807.67 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37,269.79 | 2021-2025 | Jardiance |
| Abbott Laboratories | $22,674.86 | 2019-2025 | Cardiomems, Amplatzer Amulet, Mitraclip |
| Lilly USA, LLC | $16,292.15 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $14,415.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $11,366.40 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $4,943.26 | 2021-2024 | Farxiga, Brilinta, Wainua |
| Medtronic, INC. | $2,524.63 | 2021-2025 | Venaseal, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,751.28 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $1,557.35 | 2021-2025 | Avvigo Guidance System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $1,118.00 | 2020-2025 | Impella |
| Cvrx, INC. | $830.72 | 2021-2025 | Barostim Neo System |
| Novo Nordisk INC | $386.31 | 2021-2025 | Wegovy |
| Edwards Lifesciences Corporation | $370.48 | 2021-2025 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $354.27 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $266.91 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $240.69 | 2023-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2023-2024 | Camzyos |
| Angiodynamics, INC. | $187.08 | 2022 | |
| Scpharmaceuticals INC. | $163.13 | 2024 | |
| Esperion Therapeutics, INC. | $137.40 | 2021-2023 | Nexletol |
| Zoll Respicardia, INC. | $133.50 | 2021 | |
| Medtronic Vascular, INC. | $110.51 | 2020 | |
| Amgen INC. | $99.76 | 2022-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $98.60 | 2022-2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $68.68 | 2021-2023 | Xarelto |
| Pfizer INC. | $63.42 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $27.98 | 2024 | Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $26.27 | 2024 | Arcalyst |
| Atricure, INC. | $24.71 | 2024 | |
| Endotronix, INC. | $21.87 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas-Duythuc To listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.